Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Cracking the BAFF code

Nature Reviews Immunology volume 9, pages 491–502 (2009)Cite this article

Key Points

  • Studies examining the binding of B cell activating factor (BAFF) and APRIL (a proliferation-inducing ligand) to their receptors have revealed additional layers of complexity. Trimeric forms of both BAFF and APRIL bind to the receptor transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), but only multimeric forms of these ligands can signal through this receptor.

  • Recent work has provided a more detailed roadmap of BAFF-induced survival signalling. The activation of the alternative nuclear factor-κB2 (NF-κB2) pathway and of the phosphoinositide 3-kinase–AKT1–mammalian target of rapamycin pathway, and the upregulation of expression of myeloid cell leukaemia sequence 1 (MCL1) provide a rational basis for the effects of BAFF on B cell survival and metabolic fitness.

  • The role of BAFF is no longer restricted to B cells. BAFF is also produced by non-haematopoietic cells and affects B cells as well as T cells, macrophages and dendritic cells.

  • The role of BAFF in B cell tolerance is not what it seems. BAFF does not markedly affect the negative selection of high-affinity self-reactive B cells but instead increases the proliferation of positively selected low-affinity self-reactive B cells.

  • BAFF mediates a unique form of autoimmune disease, which is independent of T cell involvement but requires the activation of innate immune mechanisms such as Toll-like receptor activation.

  • BAFF and/or APRIL inhibitors have shown some benefits in the clinic, but there are many remaining challenges and possible future options in the form of combined therapies.

Abstract

The tumour necrosis factor (TNF) family members B cell activating factor (BAFF) and APRIL (a proliferation-inducing ligand) are crucial survival factors for peripheral B cells. An excess of BAFF leads to the development of autoimmune disorders in animal models, and high levels of BAFF have been detected in the serum of patients with various autoimmune conditions. In this Review, we consider the possibility that in mice autoimmunity induced by BAFF is linked to T cell-independent B cell activation rather than to a severe breakdown of B cell tolerance. We also outline the mechanisms of BAFF signalling, the impact of ligand oligomerization on receptor activation and the progress of BAFF-depleting agents in the clinical setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: BAFF, APRIL and their receptors.
Figure 2: The role of TRAF molecules in BAFFR signalling.
Figure 3: BAFF-dependent maturation of mouse B cells.
Figure 4: Signal transduction through BAFF receptors.
Figure 5: The potential role of excess BAFF in B cell tolerance and activation of self-reactive B cells.

Similar content being viewed by others

References

  1. Goodnow, C. C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590–597 (2005).

    Article  CAS  PubMed  Google Scholar 

  2. Hardy, R. R. & Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 19, 595–621 (2001).

    Article  CAS  PubMed  Google Scholar 

  3. Anderson, S. M., Tomayko, M. M., Ahuja, A., Haberman, A. M. & Shlomchik, M. J. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204, 2103–2114 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dillon, S. R., Gross, J. A., Ansell, S. M. & Novak, A. J. An APRIL to remember: novel TNF ligands as therapeuthic targets. Nature Rev. Drug Discov. 5, 235–246 (2006).

    Article  CAS  Google Scholar 

  5. Huard, B. et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J. Clin. Invest. 118, 2887–2895 (2008). This study highlights the relevance of APRIL binding to proteoglycans in vivo and in humans.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Schwaller, J. et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 21, 1324–1327 (2007).

    Article  CAS  PubMed  Google Scholar 

  7. Li, X. et al. Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J. Immunol. 181, 1012–1018 (2008).

    Article  CAS  PubMed  Google Scholar 

  8. Liu, Y. et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 423, 49–56 (2003). This study shows that twenty trimers of BAFF assemble in a capsid-like structure in which the receptor-binding sites remain exposed and accessible.

    Article  CAS  PubMed  Google Scholar 

  9. Bossen, C. & Schneider, P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18, 263–275 (2006).

    Article  CAS  PubMed  Google Scholar 

  10. Hymowitz, S. G. et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem. 280, 7218–7227 (2005).

    Article  CAS  PubMed  Google Scholar 

  11. Hendriks, J. et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 12, 637–648 (2005).

    Article  CAS  PubMed  Google Scholar 

  12. Ingold, K. et al. Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201, 1375–1383 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kimberley, F. C. et al. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J. 23, 1–12 (2009).

    Article  CAS  Google Scholar 

  14. Bischof, D. et al. Selective activation of TACI by syndecan-2. Blood 107, 3235–3242 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sakurai, D. et al. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 109, 2961–2967 (2007).

    CAS  PubMed  Google Scholar 

  16. Benson, M. J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655–3659 (2008).

    Article  CAS  PubMed  Google Scholar 

  17. Day, E. S. et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44, 1919–1931 (2005).

    Article  CAS  PubMed  Google Scholar 

  18. Castigli, E. et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet. 37, 829–834 (2005).

    Article  CAS  PubMed  Google Scholar 

  19. Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genet. 37, 820–828 (2005).

    Article  CAS  PubMed  Google Scholar 

  20. Bossen, C. et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111, 1004–1012 (2008). This is an in vitro demonstration that trimeric forms of BAFF and APRIL bind to the receptor TACI, but that only multimeric forms of these ligands signal through this receptor in primary B cells.

    Article  CAS  PubMed  Google Scholar 

  21. Chang, S. K., Arendt, B. K., Darce, J. R., Wu, X. & Jelinek, D. F. A role for BLyS in the activation of innate immune cells. Blood 108, 2687–2694 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chang, S. K., Mihalcik, S. A. & Jelinek, D. F. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J. Immunol. 180, 7394–7403 (2008).

    Article  CAS  PubMed  Google Scholar 

  23. Ye, H. & Wu, H. Thermodynamic characterization of the interaction between TRAF2 and TNFR peptides by isothermal titration calorimetry. Proc. Natl Acad. Sci. USA 97, 8961–8966 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Baud, V. et al. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 13, 1297–1308 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gardam, S., Sierro, F., Basten, A., Mackay, F. & Brink, R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28, 391–401 (2008).

    Article  CAS  PubMed  Google Scholar 

  26. Xie, P., Stunz, L. L., Larison, K. D., Yang, B. & Bishop, G. A. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 27, 253–267 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Xu, L.-G. & Shu, H.-B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-κB activation and IL-10 production. J. Immunol. 169, 6883–6889 (2002).

    Article  CAS  PubMed  Google Scholar 

  28. Liao, G., Zhang, M., Harhaj, E. W. & Sun, S. C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279, 26243–26250 (2004).

    Article  CAS  PubMed  Google Scholar 

  29. Matsuzawa, A. et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321, 663–668 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nature Immunol. 9, 1364–1370 (2008).

    Article  CAS  Google Scholar 

  31. Mackay, F., Schneider, P., Rennert, P. & Browning, J. L. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231–264 (2003).

    Article  CAS  PubMed  Google Scholar 

  32. Scapini, P., Bazzoni, F. & Cassatella, M. A. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol. Lett. 116, 1–6 (2008).

    Article  CAS  PubMed  Google Scholar 

  33. Boule, M. W. et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin–immunoglobulin G complexes. J. Exp. Med. 199, 1631–1640 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Mackay, F. & Leung, H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 18, 284–289 (2006).

    Article  CAS  PubMed  Google Scholar 

  35. Chu, V. T., Enghard, P., Riemekasten, G. & Berek, C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J. Immunol. 179, 5947–5957 (2007).

    Article  CAS  PubMed  Google Scholar 

  36. Kern, C. et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103, 679–688 (2004).

    Article  CAS  PubMed  Google Scholar 

  37. Langat, D. L., Wheaton, D. A., Platt, J. S., Sifers, T. & Hunt, J. S. Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta. Am. J. Pathol. 172, 1303–1311 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Alsaleh, G. et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by α5β1 integrin stimulation and is negatively regulated by tumor necrosis factor α and Toll-like receptor ligands. Arthritis Rheum. 56, 3202–3214 (2007).

    Article  CAS  PubMed  Google Scholar 

  39. Abe, M. et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI–Fc treatment in patients with multiple myeloma. Leukemia 20, 1313–1315 (2006).

    Article  CAS  PubMed  Google Scholar 

  40. Geffroy-Luseau, A., Jego, G., Bataille, R., Campion, L. & Pellat-Deceunynck, C. Osteoclasts support the survival of human plasma cells in vitro. Int. Immunol. 20, 775–782 (2008).

    Article  CAS  PubMed  Google Scholar 

  41. Kato, A., Truong-Tran, A. Q., Scott, A. L., Matsumoto, K. & Schleimer, R. P. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-β-dependent mechanism. J. Immunol. 177, 7164–7172 (2006).

    Article  CAS  PubMed  Google Scholar 

  42. Ittah, M. et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur. J. Immunol. 39, 1–9 (2008).

    Google Scholar 

  43. Pelekanou, V. et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 8, 76 (2008).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Krumbholz, M. et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195–200 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Thangarajh, M., Masterman, T., Hillert, J., Moerk, S. & Jonsson, R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand. J. Immunol. 65, 92–98 (2007).

    Article  CAS  PubMed  Google Scholar 

  46. Darce, J. R., Arendt, B. K., Wu, X. & Jelinek, D. F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179, 7276–7286 (2007).

    Article  CAS  PubMed  Google Scholar 

  47. Ng, L. G. et al. BAFF-R is the principal BAFF receptor facilitating BAFF co-stimulation of B and T cells. J. Immunol. 173, 807–817 (2004).

    Article  CAS  PubMed  Google Scholar 

  48. Mackay, F. & Schneider, P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 19, 263–276 (2008).

    Article  CAS  PubMed  Google Scholar 

  49. O'Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–97 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Groom, J. R. et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204, 1959–1971 (2007). This study shows that autoimmunity in Baff -transgenic mice is T cell independent. Several lines of evidence indicate that autoimmunity correlates with reciprocal induction and activation of TACI and TLRs on innate-like B cells.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Allman, D., Srivastava, B. & Lindsley, R. C. Alternative route to maturity: branch points and pathways for generating follicular and marginal zone B cells. Immunol. Rev. 197, 147–160 (2004).

    Article  CAS  PubMed  Google Scholar 

  52. Pillai, S., Cariappa, A. & Moran, S. T. Marginal zone B cells. Annu. Rev. Immunol. 23, 16–19 (2005).

    Article  CAS  Google Scholar 

  53. Meyer-Bahlburg, A., Andrews, S. F., Yu, K. O., Porcelli, S. A. & Rawlings, D. J. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J. Exp. Med. 205, 155–168 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Crowley, J. E. et al. Homeostatic control of B lymphocyte subsets. Immunol. Res. 42, 75–83 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  55. Gorelik, L. et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 198, 937–945 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Scholz, J. L. et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad. Sci. USA 105, 15517–15522 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hardenberg, G., van Bostelen, L., Hahne, M. & Medema, J. P. Thymus-independent class switch recombination is affected by APRIL. Immunol. Cell. Biol. 86, 530–534 (2008).

    Article  CAS  PubMed  Google Scholar 

  58. Belnoue, E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755–2764 (2008).

    Article  CAS  PubMed  Google Scholar 

  59. Castigli, E. et al. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201, 35–39 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Mackay, F., Sierro, F., Grey, S. T. & Gordon, T. P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243–265 (2005).

    Article  CAS  PubMed  Google Scholar 

  61. He, B. et al. Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26, 812–826 (2007).

    Article  CAS  PubMed  Google Scholar 

  62. Massacand, J. C. et al. Intestinal bacteria condition dendritic cells to promote IgA production. PLoS ONE 3, e2588 (2008).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Varfolomeev, E. et al. APRIL-deficient mice have normal immune system development. Mol. Cell. Biol. 24, 997–1006 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Mantchev, G. T., Cortesao, C. S., Rebrovich, M., Cascalho, M. & Bram, R. J. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J. Immunol. 179, 2282–2288 (2007).

    Article  CAS  PubMed  Google Scholar 

  65. Yang, M. et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2814–2824 (2005).

    Article  CAS  PubMed  Google Scholar 

  66. Patke, A., Mecklenbrauker, I., Erdjument-Bromage, H., Tempst, P. & Tarakhovsky, A. BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism. J. Exp. Med. 203, 2551–2562 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Woodland, R. T. et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111, 750–760 (2008). References 66 and 67 show the essential roles of the kinases mTOR and PIM2 in mediating the cellular growth and survival effects of BAFF on B cells.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Enzler, T. et al. Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25, 403–415 (2006).

    Article  CAS  PubMed  Google Scholar 

  69. Opferman, J. T. et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101–1104 (2005).

    Article  CAS  PubMed  Google Scholar 

  70. Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671–676 (2003).

    Article  CAS  PubMed  Google Scholar 

  71. Wang, J. M. et al. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 19, 6195–6206 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Mills, J. R. et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl Acad. Sci. USA 105, 10853–10858 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to prelude autoimmunity. Science 286, 1735–1738 (1999).

    Article  CAS  PubMed  Google Scholar 

  74. Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E. & Green, D. R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell. 21, 749–760 (2006).

    Article  CAS  PubMed  Google Scholar 

  75. Sitailo, L. A., Tibudan, S. S. & Denning, M. F. The protein kinase Cδ catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J. Biol. Chem. 281, 29703–29710 (2006).

    Article  CAS  PubMed  Google Scholar 

  76. Grumont, R. J., Strasser, A. & Gerondakis, S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-κB regulated c-myc transcription. Mol. Cell 10, 1283–1294 (2002).

    Article  CAS  PubMed  Google Scholar 

  77. Sakurai, D. et al. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur. J. Immunol. 37, 110–118 (2007).

    Article  CAS  PubMed  Google Scholar 

  78. Katsenelson, N. et al. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 37, 1785–1795 (2007).

    Article  CAS  PubMed  Google Scholar 

  79. Acosta-Rodriguez, E. V. et al. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur. J. Immunol. 37, 990–1000 (2007).

    Article  CAS  PubMed  Google Scholar 

  80. Stadanlick, J. E. & Cancro, M. P. BAFF and the plasticity of peripheral B cell tolerance. Curr. Opin. Immunol. 20, 158–161 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Ait-Azzouzene, D., Gavin, A. L., Skog, P., Duong, B. & Nemazee, D. Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igκ-reactive macroself antigen. Eur. J. Immunol. 36, 985–996 (2006).

    Article  CAS  PubMed  Google Scholar 

  82. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004). This paper shows that BAFF overexpression does not prevent the negative selection of high-affinity self-reactive B cells in a complex B cell repertoire but instead expands low-affinity self-reactive B cell populations, which are probably positively selected.

    Article  CAS  PubMed  Google Scholar 

  83. Gaudin, E. et al. Positive selection of B cells expressing low densities of self-reactive BCRs. J. Exp. Med. 199, 843–853 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Lam, K. P., Kühn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid death. Cell 90, 1073–1083 (1997).

    Article  CAS  PubMed  Google Scholar 

  85. Wen, L. et al. Evidence of marginal-zone B cell-positive selection in spleen. Immunity 23, 297–308 (2005).

    Article  CAS  PubMed  Google Scholar 

  86. Hondowicz, B. D. et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int. Immunol. 19, 465–475 (2007).

    Article  CAS  PubMed  Google Scholar 

  87. Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).

    Article  CAS  PubMed  Google Scholar 

  88. Hoffman, R. W. T cells in the pathogenesis of systemic lupus erythematosus. Clin. Immunol. 113, 4–13 (2004).

    Article  CAS  PubMed  Google Scholar 

  89. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nature Rev. Immunol. 6, 823–835 (2006).

    Article  CAS  Google Scholar 

  90. Herlands, R. A., Christensen, S. R., Sweet, R. A., Hershberg, U. & Shlomchik, M. J. T cell-independent and Toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 29, 249–260 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Batten, M. et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphomas. J. Immunol. 172, 812–822 (2004).

    Article  CAS  PubMed  Google Scholar 

  92. Fletcher, C. A. et al. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36, 2504–2514 (2006).

    Article  CAS  PubMed  Google Scholar 

  93. Ng, L. G. et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36, 1837–1846 (2006).

    Article  CAS  PubMed  Google Scholar 

  94. Treml, L. S. et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 178, 7531–7539 (2007).

    Article  CAS  PubMed  Google Scholar 

  95. Mackay, F. & Tangye, S. G. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr. Opin. Pharmacol. 4, 347–354 (2004).

    Article  CAS  PubMed  Google Scholar 

  96. Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).

    Article  CAS  PubMed  Google Scholar 

  97. Ding, C. & Jones, G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs 7, 464–472 (2006).

    CAS  PubMed  Google Scholar 

  98. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).

    Article  CAS  PubMed  Google Scholar 

  99. Carbonatto, M. et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol. Sci. 105, 200–210 (2008).

    Article  CAS  PubMed  Google Scholar 

  100. Munafo, A., Priestley, A., Nestorov, I., Visich, J. & Rogge, M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur. J. Clin. Pharmacol. 63, 647–656 (2007).

    Article  CAS  PubMed  Google Scholar 

  101. Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305–317 (2006).

    Article  CAS  PubMed  Google Scholar 

  102. Vugmeyster, Y. et al. A soluble BAFF antagonist, BR3–Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168, 476–489 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Pillai, S. & Cariappa, A. The bone marrow perisinusoidal niche for recirculating B cells and the positive selection of bone marrow-derived B lymphocytes. Immunol. Cell Biol. 87, 16–19 (2009).

    Article  CAS  PubMed  Google Scholar 

  104. Krumbholz, M. et al. Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131, 1455–1463 (2008).

    Article  CAS  PubMed  Google Scholar 

  105. Pers, J. O. et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 56, 1464–1477 (2007).

    Article  PubMed  Google Scholar 

  106. Salzer, U. et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113, 1967–1976 (2008).

    Article  PubMed  CAS  Google Scholar 

  107. Garibyan, L. et al. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J. Clin. Invest. 117, 1550–1557 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Rizzi, M. et al. BAFF receptor expression in CVID patients. Clin. Immunol. 123, S15 (2007).

    Article  Google Scholar 

  109. Carey, J. B., Moffatt-Blue, C. S., Watson, L. C., Gavin, A. L. & Feeney, A. J. Repertoire-based selection into the marginal zone compartment during B cell development. J. Exp. Med. 205, 2043–2052 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Wardemann, H., Boehm, T., Dear, N. & Carsetti, R. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J. Exp. Med. 195, 771–780 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Teague, B. N. et al. Cutting edge: transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J. Immunol. 178, 7511–7515 (2007).

    Article  CAS  PubMed  Google Scholar 

  112. Gorelik, L. et al. BAFF regulates CD21/35 and CD23 expression independently of its B cell survival function. J. Immunol. 172, 762–766 (2004).

    Article  CAS  PubMed  Google Scholar 

  113. Shimomura, Y. et al. A unique B2 B cell subset in the intestine. J. Exp. Med. 205, 1343–1355 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Shulga-Morskaya, S. et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173, 2331–2341 (2004).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank S. Gardam for assistance with the design of Fig. 2. This work was funded by grants from The National Health and Medical Research Council (NHMRC) of Australia, the New South Wales Lupus association and the Nancy E. Pendergast Charitable Trust Fund Perpetual (to F.M.), and the Swiss National Science Foundation (to P.S.). We apologise to the many authors who have contributed to this field but have not been cited in this manuscript owing to referencing restrictions.

Author information

Author notes

  1. Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, Epalinges, CH-1066, Switzerland.

Authors and Affiliations

  1. Department of Immunology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Alfred Hospital, 86 Commercial Road, Melbourne, 3004, Victoria, Australia

    Fabienne Mackay & Pascal Schneider

Authors
  1. Fabienne Mackay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabienne Mackay.

Related links

Related links

FURTHER INFORMATION

Fabienne Mackay's homepage

Glossary

B cell receptor (BCR) editing

The process of inducing somatic mutations that selectively alter the sequence and specificity of the B cell receptor.

Trans-splicing

Splicing of a pre-mRNA spanning two adjacent genes.

Classical NF-κB pathway

An IKKγ (inhibitor of nuclear factor-κB (NF-κB) kinase-γ)-dependent signalling pathway that activates the transcription factor NF-κB, which usually contains the p50 subunit derived from the p105 NF-κB1 precursor.

Alternative NF-κB pathway

A signalling cascade resulting in the IKKγ (inhibitor of nuclear factor-κB (NF-κB) kinase-γ)-independent activation of the transcription factor NF-κB. Hallmarks of this pathway are the activation of NF-κB-inducing kinase and the processing of NF-κB2 from a p100 precursor to a p52 fragment.

Cytotrophoblast

A cell of the inner layer of the trophoblast, which is the outermost layer in an embryo that functions to anchor the embryo to the maternal endometrium.

Marginal zone B cell

A B cell that resides in the marginal zone, a region at the interface between the non-lymphoid red pulp and the lymphoid white pulp of the spleen.

B1 B cell

A cell belonging to a sub-class of B cells that reside mainly in the peritoneal and pleural cavities, that express IgM in greater quantities than IgG and the receptors of which are polyspecific (that is, they have low affinities for many different antigens).

Class switching

The somatic recombination process by which immunoglobulin isotypes are switched from IgM to IgG, IgA or IgE. This imparts flexibility to the humoral immune response and allows it to exploit the different capacities of these antibody classes to activate the appropriate downstream effector mechanisms.

Heparitinase

An enzyme that catalyses the eliminative cleavage of glycosidic bonds in heparan sulphate.

T cell-independent type II humoral immune response

Type of B cell activation in which several of the same antigen are presented in a way that causes cross-linking of antibodies on the surface of B cells, without requiring T cell help.

mTOR complex 1

A multiprotein complex containing mammalian target of rapamycin (mTOR), which functions as a nutrient, energy and redox sensor and controls protein synthesis. The activity of this complex is stimulated, among others, by insulin, growth factors and amino acids.

Atrophy

Cellular wasting resulting in volume loss and decreased protein content. It is the opposite of cell growth.

Systemic lupus erythematosus

(SLE). An autoimmune disease in which autoantibodies that are specific for DNA, RNA or proteins associated with nucleic acids form immune complexes that damage small blood vessels, particularly in the kidney. Patients with SLE generally have abnormal B and T cell function.

Vascular sinusoid

A specialized blood vessel in haematopoietic tissues through which venous circulation occurs and that has thin walls formed by a discontinuous, irregularly shaped endothelium that allows cells to pass in and out of the circulation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackay, F., Schneider, P. Cracking the BAFF code. Nat Rev Immunol 9, 491–502 (2009). https://doi.org/10.1038/nri2572

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nri2572

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing